Maze Therapeutics, Inc.

NasdaqGM:MAZE Stock Report

Market Cap: US$1.3b

Maze Therapeutics Management

Management criteria checks 4/4

Maze Therapeutics' CEO is Jason Coloma, appointed in Jul 2019, has a tenure of 6.92 years. total yearly compensation is $3.46M, comprised of 18.2% salary and 81.8% bonuses, including company stock and options. directly owns 0.67% of the company’s shares, worth $8.92M. The average tenure of the management team and the board of directors is 2.4 years and 5.4 years respectively.

Key information

Jason Coloma

Chief executive officer

US$3.5m

Total compensation

CEO salary percentage18.19%
CEO tenure6.9yrs
CEO ownership0.7%
Management average tenure2.4yrs
Board average tenure5.4yrs

Recent management updates

Recent updates

Seeking Alpha • Mar 27

Maze Therapeutics: MZE829 Presses Forward Despite Stock Price Drop

Summary I am initiating coverage on Maze Therapeutics (MAZE) with a "Buy" rating following positive phase 2 HORIZON data for MZE829 in APOL1-mediated kidney disease. MZE829 achieved a 35.6% mean reduction in proteinuria, exceeding the ≥30% uACR threshold required for clinical relevance and potential regulatory advancement. Despite a 37% stock drop post-data, I view the market reaction as overblown given the program’s success and planned pivotal trial initiation. The company maintains a strong cash position, funding operations into 2028, and has pipeline optionality with MZE782 targeting PKU and CKD in upcoming POC studies. Read the full article on Seeking Alpha
Analysis Article • Dec 15

We're Not Worried About Maze Therapeutics' (NASDAQ:MAZE) Cash Burn

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Mar 26

Maze Therapeutics: Interesting Science But IPO-Related And Other Risks Exist

Summary Maze Therapeutics, a kidney disease therapy developer, recently IPO-ed with a market cap of $487mn and significant early-stage investor backing. Lead asset MZE829 targets APOL1 Kidney Disease, showing promise in preclinical studies and currently in a phase 2 trial. Financials reveal a cash runway of 6.4 quarters from September, with significant R&D and G&A expenses, and a potential price drop post-lockup period. Due to the lack of proof of concept and potential pricing pressures, I recommend avoiding investment in Maze Therapeutics for now. Read the full article on Seeking Alpha

CEO Compensation Analysis

How has Jason Coloma's remuneration changed compared to Maze Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

-US$123m

Dec 31 2025US$3mUS$629k

-US$131m

Sep 30 2025n/an/a

-US$101m

Jun 30 2025n/an/a

-US$74m

Mar 31 2025n/an/a

-US$26m

Dec 31 2024US$6mUS$527k

US$3m

Compensation vs Market: Jason's total compensation ($USD3.46M) is below average for companies of similar size in the US market ($USD5.30M).

Compensation vs Earnings: Jason's compensation has been consistent with company performance over the past year.

CEO

Jason Coloma (50 yo)

6.9yrs
Tenure
US$3,458,267
Compensation

Dr. Jason V. Coloma, Ph D., M.P.H., MBA, is Director of Ollin Biosciences Inc. He has been Director of Braveheart Bio, Inc. since November 2025. He serves as the Chief Executive Officer and Director of Maz...

Leadership Team

NamePositionTenureCompensationOwnership
Jason Coloma
CEO & Director6.9yrsUS$3.46m0.67%
$ 8.9m
Misbah Tahir
CFO & Principal Accounting Officerless than a yearUS$3.96m0%
$ 0
Harold Bernstein
President of Research & Development and Chief Medical Officer3.1yrsUS$1.82m0%
$ 0
Vipin Vijayakumar
Vice President of R&D Infrastructure and Operationsno datano datano data
Courtney Phillips
General Counsel & Corporate Secretary1.9yrsUS$2.22m0%
$ 0
Matt Krause
Senior Vice President of Human Resourcesno datano datano data
Atul Dandekar
Chief Strategy & Business Officer5.3yrsno data0.045%
$ 593.6k
Nazila Habibizad
Senior Vice President of Technical Operations & Supply Chain2.4yrsno datano data
Maarten Hoek
Senior Vice President of Research2.4yrsno datano data
Winston Tse
Senior Vice President of Drug Discovery2.4yrsno datano data
Susan Limb
Senior Vice President of Clinical Developmentno datano datano data
Andrew Good
VP & Corporate Controllerno datano datano data
2.4yrs
Average Tenure
52.5yo
Average Age

Experienced Management: MAZE's management team is considered experienced (2.4 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Jason Coloma
CEO & Director6.9yrsUS$3.46m0.67%
$ 8.9m
Daniel Spiegelman
Independent Non-Employee Director5.7yrsUS$348.98k0%
$ 0
Charles Homcy
Directorno dataUS$602.07k0.056%
$ 744.6k
Richard Scheller
Independent Non-Employee Director7yrsUS$405.91k0%
$ 0
Jonathan Lim
Independent Non-Employee Director6.7yrsUS$344.24k0.037%
$ 496.4k
Catherine Sohn
Independent Non-Employee Director5.4yrsUS$343.66k0%
$ 0
Neil Exter
Independent Non-Employee Director1.4yrsUS$488.67k0%
$ 0
Neil Kumar
Independent Directorless than a yearno datano data
Herve Hoppenot
Chairman of the Boardless than a yearUS$738.73k0%
$ 0
Nancy Andrews
Independent Non-Employee Director5.4yrsUS$345.49k0%
$ 0
5.4yrs
Average Tenure
67.5yo
Average Age

Experienced Board: MAZE's board of directors are considered experienced (5.4 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/10 01:04
End of Day Share Price 2026/06/10 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Maze Therapeutics, Inc. is covered by 12 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Julian HarrisonBTIG
Debjit ChattopadhyayGuggenheim Securities, LLC
Ananda GhoshH.C. Wainwright & Co.